Aktis Oncology Inc (AKTS)

Apr 13, 2026

Top Cybin (HELP) Competitors 2026 - MarketBeat

Apr 13, 2026

Apr 12, 2026

H.C. Wainwright Raises its Price Target on Aktis Oncology (AKTS) to $33 - Insider Monkey

Apr 12, 2026

Apr 12, 2026

5 Healthcare Stocks Insiders Are Buying - Insider Monkey

Apr 12, 2026

Apr 10, 2026

Biopharma IPOs Had Their Best Showing In More Than A Year In Q1 - Citeline News & Insights

Apr 10, 2026

Apr 08, 2026

AMPH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Apr 02, 2026

Aktis Oncology, Inc.: Fundamental Analysis and Financial Ratings | AKTS | US01021M1045 - marketscreener.com

Apr 02, 2026

Mar 31, 2026

Aktis Oncology: Accelerated Pipeline Progress and High-Value Clinical Catalysts Underpin Buy Rating and $34 Target - TipRanks

Mar 31, 2026

Mar 31, 2026

Aktis Oncology (AKTS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $AKTS - MarketBeat

Mar 31, 2026

Mar 31, 2026

Aktis Oncology’s AKY-2519 gains IND approvals - BioWorld MedTech

Mar 31, 2026

Mar 31, 2026

H.C. Wainwright raises Akoustis Technologies price target on pipeline progress - Investing.com Canada

Mar 31, 2026

Mar 31, 2026

AKTS: Analyst Raises Price Target, Maintains 'Buy' Rating | AKTS Stock News - GuruFocus

Mar 31, 2026

Mar 31, 2026

FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial By Investing.com - Investing.com Australia

Mar 31, 2026

Mar 30, 2026

Aktis Oncology (NASDAQ: AKTS) secures IND clearances and multi-year cash runway - Stock Titan

Mar 30, 2026

Mar 30, 2026

AKTS: Strong cash position post-IPO and Eli Lilly deal supports clinical pipeline through 2029 - TradingView

Mar 30, 2026

Mar 30, 2026

Aktis Oncology (NASDAQ: AKTS) outlines miniprotein alpha radiopharma strategy - Stock Titan

Mar 30, 2026

Mar 30, 2026

Aktis Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment - marketscreener.com

Mar 30, 2026

Mar 30, 2026

FDA clears Aktis Oncology’s AKY-2519 for phase 1b trial - Investing.com

Mar 30, 2026

Mar 30, 2026

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - The Manila Times

Mar 30, 2026

Mar 30, 2026

Aktis Oncology Announces FDA Clearance of Investigational - GlobeNewswire

Mar 30, 2026

Mar 30, 2026

This Aktis Oncology analyst begins coverage on a bullish note; here are top 5 initiations for Monday - MSN

Mar 30, 2026

Mar 28, 2026

USA Stocks: Research Stocks from USA Stock Market - GuruFocus

Mar 28, 2026

Mar 26, 2026

AKTS (Aktis Oncology) PB Ratio : (As of Mar. 26, 2026) - gurufocus.com

Mar 26, 2026

Mar 22, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P TMI Index - MarketScreener

Mar 22, 2026

Mar 19, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell 3000E Value Benchmark - marketscreener.com

Mar 19, 2026

Mar 19, 2026

Aktis Oncology, Inc.(NasdaqGS: AKTS) added to Russell 3000E Growth Index - marketscreener.com

Mar 19, 2026

Mar 17, 2026

Huge insider buying now at this insurance giant and 2 biotechs - msn.com

Mar 17, 2026

Mar 14, 2026

Aktis Oncology (AKTS) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 14, 2026

Mar 11, 2026

Little-known Cambridge firm plans public debut to fund pancreatic cancer trial - The Business Journals

Mar 11, 2026

Mar 10, 2026

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail

Mar 10, 2026

Mar 09, 2026

AKTS: Innovative radiopharmaceutical platform advances with strong pipeline, partnerships, and cash runway - TradingView

Mar 09, 2026

Mar 09, 2026

AKTS: Innovative radiopharmaceutical platform targets major cancer types, backed by strong pipeline and funding - TradingView

Mar 09, 2026

Mar 09, 2026

This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 09, 2026

Mar 08, 2026

Aktis Oncology Fast Track Win Highlights AKY-1189 Potential And Key Risks - Sahm

Mar 08, 2026

Mar 06, 2026

Assessing Aktis Oncology (AKTS) Valuation After Recent Share Price Momentum And Ongoing Losses - Sahm

Mar 06, 2026

Mar 05, 2026

Aktis Oncology, Inc. (AKTS) Presents at TD Cowen 46th Annual Health Care ConferenceSlideshow - Seeking Alpha

Mar 05, 2026

Mar 04, 2026

Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors - TipRanks

Mar 04, 2026

Mar 03, 2026

AKTS: New miniprotein radiopharmaceuticals target broad solid tumor markets, advancing in clinic - TradingView

Mar 03, 2026

Mar 03, 2026

AKTS: Lead radiopharmaceutical assets advance toward major milestones in a rapidly expanding market - TradingView

Mar 03, 2026

Feb 28, 2026

BUDA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Feb 28, 2026

Feb 28, 2026

AKTS Technical Analysis & Stock Price Forecast - Intellectia AI

Feb 28, 2026

Feb 27, 2026

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer - Reuters

Feb 27, 2026

Feb 25, 2026

Assessing Aktis Oncology (AKTS) Valuation As Shares Show Short Term Momentum Rebound - Yahoo Finance

Feb 25, 2026

Feb 25, 2026

Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target - TipRanks

Feb 25, 2026

Feb 24, 2026

Aktis Oncology to Present at Upcoming March Investor Conferences - The Manila Times

Feb 24, 2026

Feb 24, 2026

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - Bitget

Feb 24, 2026

Feb 24, 2026

Aktis Oncology receives U.S. FDA fast track designation for Aky-1189 - marketscreener.com

Feb 24, 2026

Feb 24, 2026

IPO Tracker 2026: Generate’s IPO Could Reach $425M, Largest Raise Yet - BioSpace

Feb 24, 2026